Prabhudas Lilladher recommended hold rating on Sun Pharmaceutical Industries with a target price of Rs 436 in its research report dated May 21, 2020.
Prabhudas Lilladher's research report on Sun Pharmaceutical Industries
Taro Pharma's sales was US$180m in Q4FY20 v/s US$148m in Q3FY20. Gross margin however declined to 58% v/s 64% QoQ reflecting an ongoing price erosion in US derma segment. The decline attributed to an unfavorable product mix, mainly contributed by derma products. The company has huge stock of medicines to avoid any shortage post COVID. While US generic price stabilized at 5-7%, Taro continued to face challenges through large revenue exposure (55-60%) and EBITDA contributions (70-75%) from derma products in US portfolio.
Taro Q1FY21E sales are likely to be in the range of US$135-145m with gross margin of 55-60%. Taro's disappointment in the US market would continue be a biggest overhang in SUNP earnings which contribute 40-45% to the overall US revenues. We maintain 'Hold' on SUNP and retain TP of Rs436.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Facebook-BCG report suggests these measures for businesses to unlock the changing consumer behaviour in the current pandemic. Read More!